VANCOUVER, CANADA: Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity drug development, says the latest results from a clinical trial with a competitor’s SGLT Inhibitor, demonstrates the major opportunity for the company with its unique molecules.
Sirona Biochem CEO, Dr. Howard Verrico, said, “New data on dapagliflozin reported at the recent 20th. World Diabetes Congress in Montreal shows SGLT2 inhibitor dapagliflozin lowered levels of HbA1c blood sugar significantly more than the placebo and that it was safe and well tolerated with no treatment-related serious adverse events 1. That is why SGLT inhibitors are deservedly attracting worldwide attention from major pharmaceutical companies around the world.
“Furthermore, dapagliflozin was effective in patients regardless of disease stage and was associated with continuous weight loss and lowered glycemia without significant hypoglycemia 2,” stated Dr. Verrico.
“The opportunity for Sirona Biochem is its unique SGLT2 chemistry we anticipate will prove even more robust and efficacious. What we have recently done is show that our molecules, with their unique GlycoMim® technology, can inhibit the glucose transporter SGLT2, which is the protein that allows the body to re-absorb almost 100 percent of sugars that would otherwise have been excreted – an ability that was most useful in the days when diets were generally sugar free,” commented Dr. Verrico.
The double-blind, multicenter, phase III study involved 274 patients with HbA1c of 7.0-10.0%, dapagliflozin 2.5, 5 or 10 mg or placebo was administered each morning for 24 weeks. The mean reductions of HbA1c in these treatment groups were -0.58, -0.77, -0.89 and -0.23%, respectively, while the mean reductions of fasting plasma glucose were -15, -24, -29 and -4 mg/dL, respectively.
According to the Canadian Diabetes Association, more than two million people in Canada, representing over 6% of the population, suffer from diabetes. There are 23.6 million children and adults in the United States, or 7.8% of the population, who have the disease.
Diabetes is a chronic disease in which the body does not produce or properly use insulin. Insulin is a hormone that is needed to convert sugars and other nutrients into glucose, which is the body’s ‘fuel’ for functioning, but modern diets expose many people to chronically excessive amounts of sugars which are almost totally re-absorbed .
Sirona Biochem owns the worldwide exclusive product rights to a library of unique SGLT inhibitors to treat diabetes and obesity through its strategic partnership with TFChem, a drug discovery company based in Rouen, France.
Sirona Biochem’s website is at: www.sironabiochem.com. Investors can e-mail correspondence to email@example.com , or call John Dougherty, Corporate Development, at 604-641-4466. For media relations, call Nigel Horsley at 604-689-8833.
Sirona Biochem Corp. (TSX: V – SBM) is an emerging biotech company dedicated to the discovery and development of novel drug compounds. The current focus is on treatments for Type II diabetes and obesity. Sirona has entered into a license agreement with TFChem S.A.R.L., a drug discovery company based in Rouen, France. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development, to biotech companies. The license agreement with TFChem provides for research and development of new compounds known as SGLT Inhibitors.
1. Ferrannini, E. et al. 20th World Diabet Congr (Oct 18-22, Montreal) 2009, Abst O-0536).
2. Bastien, A. et al. 20th World Diabet Congr (Oct 18-22, Montreal) 2009, Abst D-0765).
President and Director
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.